Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514298 | 0.93 | GPR119 (0.54) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL514127 | 0.92 | GPR119 (0.54) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL514634 | 0.89 | GPR119 (0.52) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL514577 | 0.88 | GPR119 (0.52) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL515365 | 0.87 | GPR119 (0.52) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL514892 | 0.86 | GPR119 (0.51) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL513996 | 0.86 | GPR119 (0.54) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL514968 | 0.85 | GPR119 (0.53) | GPR119SCN9ACNR2CYP3A4CYP2C19 | |
| SCHEMBL514719 | 0.85 | GPR119 (0.52) | GPR119SCN9ACYP3A4CYP2C19 | |
| SCHEMBL514638 | 0.84 | GPR119 (0.65) | GPR119CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742117-B2 | Oxime derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-03 | — | — | US | claimed |
| EP-2379542-B1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2013-02-13 | — | — | EP | claimed |
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | US | claimed |
| EP-2379542-A1 | NOVEL OXIME DERIVATIVES | Cadila Healthcare Limited (IN) | 2011-10-26 | — | — | EP | claimed |
| WO-2010084512-A1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2010-07-29 | — | — | WO | claimed |
| US-8742117-B2 | Oxime derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-03 | — | — | US | disclosed |
| EP-2379542-B1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2013-02-13 | — | — | EP | disclosed |
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| EP-2379542-A1 | NOVEL OXIME DERIVATIVES | Cadila Healthcare Limited (IN) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010084512-A1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CYP11B2, CYP11B1, PYGL | GPR119 382/4885SCN9A 2182/4885CNR2 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.